Merck: Positive Developments, But Watch The Q2 Earnings

JHVEPhoto/iStock Editorial via Getty Images Since I last wrote about the pharmaceuticals stock Merck & Co., Inc. (NYSE:MRK) in April, its share price has seen a small decline, after a 20% rise in the first quarter of 2024 (Q1 2024). While the developments for the company have been broadly positive since, there are some emerging risk as well. Here, I assess how the balance of the supporting factors and the potential drags sits and what it means for the price going forward. Keytruda stays the highlight Fi ...